Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vose

Showing results (551-560 of 891) with videos related to

Pageof 90
Sort By:
British Journal of Haematology|April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II studyJulie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decadesVijaya Raj Bhatt, Fausto R Loberiza, Hongmei Jing, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
British Journal of Clinical Pharmacology|January 1, 1979
Pharmacokinetics of propantheline bromide in normal manC W Vose, G C Ford, S J Grigson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial responseMarcie R Tomblyn, Marian Ewell, Christopher Bredeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicityJ M Vose, P J Bierman, J R Anderson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphomaJulie M Vose, Philip J Bierman, Fausto R Loberiza, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
Scientific Reports|August 31, 2017
Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastomaThomas Ströbel, Sibylle Madlener, Serkan Tuna, et al.
Pageof 90

Showing results (551-560 of 891) with videos related to

Sort By:
Pageof 90
British Journal of Haematology|April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II studyJulie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decadesVijaya Raj Bhatt, Fausto R Loberiza, Hongmei Jing, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
British Journal of Clinical Pharmacology|January 1, 1979
Pharmacokinetics of propantheline bromide in normal manC W Vose, G C Ford, S J Grigson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2010
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial responseMarcie R Tomblyn, Marian Ewell, Christopher Bredeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicityJ M Vose, P J Bierman, J R Anderson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 4, 2012
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphomaJulie M Vose, Philip J Bierman, Fausto R Loberiza, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
Scientific Reports|August 31, 2017
Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastomaThomas Ströbel, Sibylle Madlener, Serkan Tuna, et al.
Pageof 90